Prelude Therapeutics
PRLD
56 hedge funds and large institutions have $150M invested in Prelude Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 10 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
32% more capital invested
Capital invested by funds: $113M → $150M (+$36.4M)
0% more call options, than puts
Call options by funds: $4K | Put options by funds: $4K
2.92% less ownership
Funds ownership: 66.8% → 63.88% (-2.9%)
7% less funds holding
Funds holding: 60 → 56 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$12.6M |
| 2 |
Morgan Stanley
New York
|
+$1.08M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$340K |
| 4 |
Renaissance Technologies
New York
|
+$234K |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.58M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$623K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$618K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$218K |
PRLD Hedge Fund Activity: Q4 2023 in Review
56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2023, worth a combined $150M — up 32% from $113M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PRLD and 6 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 29 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $12.6M. The largest seller was Fidelity Investments, cutting an estimated $14.8M.
- 56 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2023, down from 60 in Q3 2023.
- Funds reported $150M of Prelude Therapeutics stock for Q4 2023, up 32% quarter-over-quarter.
- 6 funds opened new Prelude Therapeutics positions in Q4 2023 and 10 closed out, a net change of -4 holders.
- The largest Prelude Therapeutics buyer in Q4 2023 was Deerfield Management, an estimated $12.6M added.
- The largest Prelude Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $14.8M sold.
Based on aggregated 13F filings for Q4 2023.